Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact.

Dorian McIlroy1, Marc Gregoire

  • 1INSERM U419, Institut de Biologie, 9 quai Moncousu, 44000 Nantes, France.

Cancer Immunology, Immunotherapy : CII
|June 27, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural and functional analysis of natural capsid variants suggests sialic acid-independent entry of BK polyomavirus.

Cell reports·2023
Same author

A cluster of broadly neutralizing IgG against BK polyomavirus in a repertoire dominated by IgM.

Life science alliance·2023
Same author

Quantification of APOBEC3 Mutation Rates Affecting the <i>VP1</i> Gene of BK Polyomavirus In Vivo.

Viruses·2022
Same author

KRAS signaling in malignant pleural mesothelioma.

EMBO molecular medicine·2021
Same author

A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients.

Human vaccines & immunotherapeutics·2021
Same author

Non-permissive human conventional CD1c+ dendritic cells enable trans-infection of human primary renal tubular epithelial cells and protect BK polyomavirus from neutralization.

PLoS pathogens·2021
Same journal

Correction: Repurposing public sarcoma multi-omics for neoantigen discovery.

Cancer immunology, immunotherapy : CII·2026
Same journal

A low-dose self-amplifying mRNA vaccine encoding HPV16 E6/E7 induces potent T-cell immunity and antitumor protection in mice.

Cancer immunology, immunotherapy : CII·2026
Same journal

GLP-1 receptor agonists at immune checkpoint inhibitor initiation with immune-related and supportive-care outcomes in patients with cancer and overweight or obesity without diabetes: a target trial emulation.

Cancer immunology, immunotherapy : CII·2026
Same journal

Macrophage heterogeneity in breast cancer microenvironment and development of a prognostic model: exploring TFF1 as a novel therapeutic target.

Cancer immunology, immunotherapy : CII·2026
Same journal

The increased co-expression of SLC7A11 and PD-L1 was associated with poor prognosis in extranodal natural killer T-cell lymphoma patients.

Cancer immunology, immunotherapy : CII·2026
Same journal

Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation.

Cancer immunology, immunotherapy : CII·2026
See all related articles

Tumour immunotherapy with dendritic cells (DCs) shows promise. Maturation state of DCs, particularly using TNF-alpha, significantly impacts clinical responses in melanoma patients, suggesting optimization strategies.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Dendritic cell (DC) immunotherapy is an emerging approach for various cancers.
  • Clinical application of DC-based cancer immunotherapy has been explored over the last five years.

Purpose of the Study:

  • To analyze clinical outcomes of dendritic cell (DC) immunotherapy trials.
  • To evaluate the impact of DC maturation protocols on patient responses, specifically in melanoma.

Main Methods:

  • Review of ten clinical trials involving 167 melanoma patients treated with DC immunotherapy.
  • Analysis of patient responses (complete regression, partial regression, stable disease, progressive disease) in relation to DC generation protocols.

Main Results:

Related Experiment Videos

  • Favorable responses (non-progressive disease) were not linked to prior chemotherapy.
  • A significant correlation (p<0.001) was observed between favorable responses and the use of TNF-alpha for in vitro DC maturation.
  • 9 complete regressions, 24 partial regressions, and 26 cases of stable disease were observed.

    • Conclusions:

    • The maturation state of dendritic cells (DCs) significantly influences clinical responses in cancer immunotherapy.
    • Optimizing DC maturation protocols, potentially using agents like TNF-alpha, is a key strategy for improving therapeutic efficacy.
    • Further research into various DC maturation molecules and strategies is warranted to enhance treatment outcomes.